UNH’s 86.7% MCR had an $860M asterisk — plus Axon and Gartner still live Aug 4
Not everything on the August 4 tape is chips and racks — and not every clean headline number survives contact with its own press release. The example this week: UnitedHealth’s much-quoted 86.7% medical care ratio came with $860M of net favorable prior-period development attached, a footnote most recaps skipped. This checklist digests UNH (already reported July 16) and previews Axon and Gartner, the adjacent names still live in the window. Royal Caribbean printed July 28; noted only as calendar spillover from the same ticker batch.
This is research, not investment advice — if you want tips, wrong page. Figures from SEC Exhibit 99.1 filings.
Who prints when
| Ticker | Status | Last filed checkpoint |
|---|---|---|
| UNH | Already Jul 16 | Q2 Ex 99.1 — digest below |
| AXON | ~Aug 4 | Q1 Ex 99.1 (May 6) |
| IT | ~Aug 4 | Q1 Ex 99.1 (May 5) |
| RCL | Already Jul 28 | Travel adjacent — skip for thesis |
UnitedHealth — Q2 already on file (digest, not preview)
Q2 2026 Exhibit 99.1 (Jul 16; accession 0000731766-26-000191, CIK
0000731766):
| Line | Amount |
|---|---|
| Revenue | $112.0B |
| Earnings from operations | $8.0B |
| EPS / adjusted EPS | $6.04 / $6.38 |
| Medical care ratio (MCR) | 86.7% (vs 89.4% YoY) |
| UHC people served | 48.5M (−525k sequential) |
| UHC revenue / op. earnings | $86.0B / $3.9B (op. margin 4.6%) |
| Optum revenue / earnings | $65.7B / $4.0B (+160 bps margin YoY) |
| FY26 diluted EPS outlook | $18.45–$18.95 |
| FY26 adjusted EPS outlook | $19.50–$20.00 |
| FY26 MCR outlook | 88.1% ± 25 bps |
The asterisk on the headline: the 86.7% MCR was affected by $860M of net favorable prior-period reserve development, the majority of it related to 2026 dates of service. Strip the framing and the read changes — a chunk of the 270-bp YoY MCR improvement is reserve trueup, not purely underlying cost trend. That is exactly why the company still guides FY26 MCR to 88.1% ± 25 bps, well above the Q2 print.
Optum Health detail worth keeping: Q2 revenue $23.5B (−5% YoY) on ~700k fewer value-based-care patients — progress on cost management with a membership headwind.
Residual watch (post-print): underlying medical cost trend once the $860M development washes out, Medicare Advantage / Medicaid mix, whether the raised adj. EPS band holds into Q3, and Optum Insight AI product conversion after the Alegeus close.
Axon — Q1 baseline into the Aug 4 print
Q1 2026 Exhibit 99.1 (May 6; CIK 0001069183):
| Line | Amount |
|---|---|
| Revenue | $807M (+34% YoY) |
| Software & Services | $355M (+35%) |
| ARR | $1.5B (+35%) |
| NRR | 125% |
| AI products | +700% YoY |
| Counter-drone | +300% YoY |
| FY revenue growth outlook (raised) | 30–32% |
| Adj. EBITDA margin frame | ~25.5% |
Q1 marked the ninth consecutive quarter of 30%+ revenue growth — the streak is the thing Tuesday either extends to ten or breaks. Axon is public-safety / software-adjacent, not hospital MCR — different risk set than UNH, same “budget execution” tape.
Aug 4 scorecard: (1) reaffirm or raise the 30–32% growth band, (2) software mix vs. devices, (3) ARR / NRR 125% hold, (4) AI and counter-drone still compounding off a small base, (5) FCF vs. growth spend.
Gartner — enterprise spend proxy on the same day
Q1 2026 Exhibit 99.1 (May 5; accession 0000749251-26-000165, CIK
0000749251):
| Line | Amount |
|---|---|
| Contract value | $5.3B (+1.0% YoY FX-neutral) |
| Revenues | $1.511B (−1.5% reported / −4.3% FX-neutral) |
| Adjusted EPS | $3.32 |
| Share repurchases (quarter) | $535M |
| Buyback authorization | Board added $600M in April 2026 |
Read that table honestly: revenue is shrinking (−1.5% reported, −4.3% FX-neutral) while adjusted EPS grows — the gap is buybacks and cost discipline, not demand. Contract value barely positive at +1.0% FX-neutral is the forward-demand tell for enterprise tech budgets (including healthcare IT). Gartner is research & advisory, not a care-delivery name.
Aug 4 scorecard: contract value re-acceleration or continued stall; whether revenue decline narrows; retention; H2 guide; Research vs. Conferences mix; pace of the fresh $600M buyback authorization.
Royal Caribbean — calendar only
RCL Q2 (Jul 28): revenue $4.8B (+6%); load factor 110%; FY revenue growth guide ~9%. Travel, not healthcare — drop from this thesis.
One scoreboard
- UNH (done) — 86.7% MCR minus the $860M development, and the $19.50–$20.00 adj. EPS band, are the real bars.
- AXON (live) — extend the 30%+ streak to a tenth quarter with software/ARR quality.
- IT (live) — contract value as the enterprise-budget tell; watch whether EPS growth keeps outrunning shrinking revenue.
- Do not confuse insurer underwriting (UNH) with public-safety software (AXON) or research wallets (IT) — same week, different models.
Headlines quoted the MCR; the filing sized the reserve release. Live multiples: UNH · AXON · IT · RCL.
Primary sources
UNH Q2 Ex 99.1 (Jul 16):
https://www.sec.gov/Archives/edgar/data/731766/000073176626000191/
(0000731766-26-000191).
AXON Q1 Ex 99.1:
accession family May 6, 2026 (axon-20260506xex991), CIK 0001069183.
IT Q1 Ex 99.1:
https://www.sec.gov/Archives/edgar/data/749251/000074925126000165/
(0000749251-26-000165).
First step: open UNH’s Q2 release and find the prior-period development sentence — one number, $860M, and you’ll read every MCR headline this quarter differently.
Research, not investment advice.